Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | SVP, Chief Legal Officer | July 09, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date July 09, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 427,953 |
Reported balance
After 2026-07-09 transaction · row 1
1 source rowRow 1 · 2026-07-09 · Sale · Disposed 12,050 · Balance 427,953 F1: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 9, 2026 23:20 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 12,050 | $6.96 | $83,912.59 |
DisclosureSEC source: 0001493152-26-032742 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,953 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 00:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 6,305 | $5.30 | $33,442.98 |
DisclosureSEC source: 0001493152-26-028019 · ownership.xml · nonDerivative · entry 2 O'Malley Brendan M. · CIK 0001884342 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,003 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 00:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 4,826 | $5.43 | $26,202.77 |
DisclosureSEC source: 0001493152-26-028019 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,308 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 01:33 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 13,578 | $5.33 | $72,382.96 |
DisclosureSEC source: 0001493152-26-003282 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,134 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 113,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-002885 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,712 F1 · shares: The restricted stock will vest one-third on each of January 20, 2027, January 20, 2028, and January 20, 2029. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 9,366 | $5.39 | $50,515.52 |
DisclosureSEC source: 0001493152-25-016544 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,763 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.35 to $5.46 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 22, 2025 Filed Sep 22, 2025 23:49 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 688 | $5.43 | $3,735.84 |
DisclosureSEC source: 0001493152-25-014527 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,129 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 17,428 | $5.86 | $102,053.14 |
DisclosureSEC source: 0001641172-25-018601 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,817 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.78 to $5.92 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 06, 2025 Filed Jun 6, 2025 21:56 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 10,470 | $6.76 | $70,777.20 |
DisclosureSEC source: 0001641172-25-014167 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,245 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.76 to $6.79 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 181 | $5.24 | $948.44 |
DisclosureSEC source: 0001493152-25-009056 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,715 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 23:58 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 115,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-003465 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,896 F1 · shares: The restricted stock will vest one-third on each of January 21, 2026, January 21, 2027 and January 21, 2028. Read SEC document |
| September 28, 2024 Filed Sep 30, 2024 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 6,579 | $5.89 | $38,750.31 |
DisclosureSEC source: 0001493152-24-038800 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,289 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon Stock | 496 | $6.02 | $2,985.92 |
DisclosureSEC source: 0001493152-24-037961 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,868 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 102,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026646 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,364 F1 · shares: The restricted stock will vest one-third on each of July 8, 2025, July 8, 2026 and July 8, 2027. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:31 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 10,951 | $4.52 | $49,498.52 |
DisclosureSEC source: 0001493152-24-023122 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,675 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 12:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon stock | 8,600 | $3.24 | $27,864.00 |
DisclosureSEC source: 0001493152-24-016064 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,718 Read SEC document |
| March 31, 2024 Filed Jun 7, 2024 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 92 | $7.25 | $667.00 |
DisclosureSEC source: 0001493152-24-023117 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,026 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| March 04, 2024 Filed Mar 12, 2024 21:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 183 | $7.81 | $1,429.23 |
DisclosureSEC source: 0001493152-24-009682 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,118 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 29, 2023 Filed Sep 29, 2023 21:16 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 6,557 | $3.93 | $25,769.01 |
DisclosureSEC source: 0001493152-23-034903 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,301 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 21, 2023 Filed Sep 22, 2023 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 563 | $3.80 | $2,139.40 |
DisclosureSEC source: 0001493152-23-033448 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,858 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 13:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon stock | 3,000 | $3.80 | $11,400.00 |
DisclosureSEC source: 0001493152-23-033000 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,421 Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:15 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 90,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-020415 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,421 F1 · shares: The restricted stock will vest one-third on each of June 5, 2024, June 5, 2025 and June 5, 2026. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:23 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 104 | $2.82 | $293.28 |
DisclosureSEC source: 0001493152-23-011036 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,519 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| March 03, 2023 Filed Mar 4, 2023 00:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 207 | $2.28 | $471.96 |
DisclosureSEC source: 0001493152-23-006714 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,623 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 21:10 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon stock | 5,869 | $3.13 | $18,369.97 |
DisclosureSEC source: 0001493152-22-035169 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,830 Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 14:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon stock | 7,500 | $3.99 | $29,925.00 |
DisclosureSEC source: 0001493152-22-033016 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,961 Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 72,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027280 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,461 F1 · shares: The restricted stock will vest 25% on each of September 28, 2023, September 28, 2024, September 28, 2025 and September 28, 2026. F2 · balance_after: On September 22, 2022, the reporting person filed a Form 4 that inadvertently reported an additional 1,360 shares of common stock as beneficially owned in Column 5. The amount disclosed in Column 5 above rectifies that error. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:36 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 479 | $3.72 | $1,781.88 |
DisclosureSEC source: 0001493152-22-026569 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,071 F1 · kind: Represents the number of shares that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock and does not represent a sale. Read SEC document |
| December 06, 2021 Filed Dec 9, 2021 00:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon stock | 8,880 | $0.57 | $5,034.96 |
DisclosureSEC source: 0001493152-21-030876 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,750 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brendan O'Malley on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 05, 2021 Filed Nov 5, 2021 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon stock | 8,880 | $0.89 | $7,894.32 |
DisclosureSEC source: 0001493152-21-027433 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,630 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brendan O'Malley on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.8801 to $0.9038, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 23:08 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon stock | 25,734 | $0.90 | $23,271.26 |
DisclosureSEC source: 0001493152-21-025348 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,510 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brendan O'Malley on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.89 to $0.9625, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 08, 2021 Filed Oct 9, 2021 00:31 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon stock | 22,763 | $1.05 | $23,914.81 |
DisclosureSEC source: 0001493152-21-025084 · ownership.xml · nonDerivative · entry 2 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,244 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brendan O'Malley on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.84 to $1.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 05, 2021 Filed Oct 9, 2021 00:31 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon stock | 2,447 | $1.05 | $2,569.35 |
DisclosureSEC source: 0001493152-21-025084 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brendan O'Malley on February 24, 2021. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:37 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 272,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001493152-21-023408 · ownership.xml · derivative · entry 2 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,000 Underlying: Common Stock · 272,000 shares Expires 2031-09-20 F2 · derivative.exercise_date: The options will vest 25% on September 20, 2022, and in 36 equal monthly installments thereafter. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:37 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 136,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-023408 · ownership.xml · nonDerivative · entry 1 O'Malley Brendan M. · CIK 0001884342 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,454 F1 · shares: The restricted stock will vest 25% on each of September 20, 2022, September 20, 2023, September 20, 2024 and September 20, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.